What should I Know Regarding Pregnancy, Nursing and Administering Allergy Relief Tablet to Children or the Elderly?

If you are PREGNANT

  • Requires a Risk/Benefit Assessment:
  • FDA B (no known animal fetal risk. Unknown human fetal risk):
  • FDA B (no known animal fetal risk. Unknown human fetal risk):
  • FDA B (no known animal fetal risk. Unknown human fetal risk):
  • No Known Fetal/Neonatal Risk:
  • Requires a Risk/Benefit Assessment:
  • Requires a Risk/Benefit Assessment:
  • Requires a Risk/Benefit Assessment:

If you are NURSING

  • Precaution: INSUFFICIENT DATA AVAILABLE; LIMITED DATA SUGGEST MINIMAL AMOUNTS EXCRETED
  • Precaution: PROBABLY COMPATIBLE PER BRIGGS;MAY CAUSE SEDATION IN NURSING INFANT.
  • Precaution: LIMITED DATA SUGGEST LOW AMOUNTS EXCRETED
  • No Known Risk: LOW LEVELS EXCRETED WITH LOW RISK FOR ADVERSE EFFECTS IN INFANT
  • Precaution: ORAL BIOAVAILABILITY LOW; INFANT EXPOSURE MAY BE MINIMAL
  • Precaution: INSUFF DATA AVAIL; MOLECULAR WT LOW ENOUGH FOR POSSIBLE BREASTMILK EXCRETION
  • Precaution: LIMITED DATA SUGGEST INCREASED DROWSINESS, AND IRRITABILITY
  • Precaution: INSUFFICIENT DATA AVAILABLE; MAY CAUSE SEDATION AND INHIBIT LACTATION
  • Precaution: DROWSINESS,IRRITABIL,REFUSAL TO FEED,HIGH PITCHED CRY,STIFF NECK IN 1 CASE

If you are an adult over 60

  • management or monitoring precaution: Neuro/Psych-Avoid in older adults with or at high risk for delirium because of inducing or worsening delirium.
  • management or monitoring precaution: Cardiovascular-Elderly are more sensitive to tachycardia and hypertensive effects. May exacerbate symptomatic coronary insufficiency. Genitourinary-May cause urinary retention. Neuro/Psych-May worsen cognitive impairment in some elderly with dementia. Insomnia risk.
  • management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Maximum of 25mg/day. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
  • management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
  • management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating agents preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
  • management or monitoring precaution: Increased risk for neurological side effects. Dosage adjustment may be required.
  • management or monitoring precaution: Decrease daily dose for declining renal function (CLCR<80ml/min).
  • management or monitoring precaution: Hepatic-Elderly may be more susceptible to hepatotoxicity. Strict adherence to a maximum daily dose is recommended, and the maximum dose recommendation varies between 3000-3800 mg depending on strength used and source of the recommendation.

Giving Allergy Relief Tablet to a child under 12

  • management or monitoring precaution: Use weight based dosing in children less than 12 years.
  • management or monitoring precaution: Safety and efficacy not established in infants age <6 months.
  • Severe Precaution: Not recommended in children under 6 years unless clinician consultation.
  • Severe Precaution: Not recommended in children under 12 years.
  • Contraindication: Possible paradoxical CNS excitation. Seizure risk in newborns.
  • Severe Precaution: Use with caution and with clinician consultation. Risk of adverse CNS effects includes sedation or paradoxical excitation.
  • management or monitoring precaution: Use with caution and with clinician consultation. Risk of adverse CNS effects include sedation or paradoxical excitation.
  • Contraindication: Possible CNS excitation and seizure risk in newborns.
  • Contraindication: Possible risk of CNS excitation, convulsions in newborns.
  • management or monitoring precaution: Use with caution and with clinician consultation. Risk of adverse CNS effects include sedation or paradoxical excitation.
  • Contraindication: Risk of CNS excitation. Do not use age <6 years without clinician consult.
  • management or monitoring precaution: Consult clinician for use age under 2 years. Safety and efficacy not established.
  • management or monitoring precaution: Safety & efficacy in children less than 6 months not established.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.